Open Access

Potential effect of Sildenafil beyond pulmonary hypertension in a patient with diffuse systemic sclerosis and cryoglobulinemic vasculitis

SpringerPlus20143:559

https://doi.org/10.1186/2193-1801-3-559

Received: 8 September 2014

Accepted: 16 September 2014

Published: 26 September 2014

Abstract

Introduction

Pulmonary arterial hypertension (PAH) is a serious complication of systemic sclerosis (SSc), has a dramatic impact on prognosis and survival and is a leading cause of death.

Case description

A 40 years old female patient with difuse cutaneous SSc (dcSSc) presented with progressive dyspnea, choking sensation, cough, abdominal distension, constipation and dysphagia to solids. The muscle power was mildly reduced and multiple purpuric eruptions were present on the legs of variable sizes. The patient was ANCA negative and had positive cryoglobulinemia. The hepatitis C virus test was positive and the skin biopsy histopathology proved small vessel (leucocytoclastic) vasculitis. The modified Rodnan total skin score (MRSS) was 37. There was deterioration of the pulmonary function tests and transesophageal echocardiography revealed PAH (RVSP 60 mmHg). Sildenafil 50 mg/day resulted in a remarkable improvement of the dyspnea and Raynauds’ with a significant improvement of the skin tightness as the MRSS became 22. The small vessel vasculitic rash remarkably improved and the RVSP became 34 mmHg with a dramatic improvement of the PAH.

Discussion and evaluation

Sildenafil enhances vasodilatation, has antiproliferative effects and is effective in the treatment of PAH. The remarkable improvement in the vasculitic skin lesions in this case after sildenafil is the second report after the described dramatic improvement of small vessel vasculitis in a case with Takayasu arteritis. The emerging trends make it necessary to exploit the full therapeutic potential of Sildenafil in scleroderma and PAH with other extrapulmonary manifestations.

Conclusion

We report a very rare association of dcSSc with small vessel cryoglobulinemic vasculitis with a remarkable improvement after sildenafil.

Keywords

Diffuse systemic sclerosis Pulmonary hypertension Cryoglobulinemic vasculitis Sildenafil

Case presentation

A 40 year-old female with diffuse cutaneous systemic sclerosis (dcSSc) for 3 years was admitted with palpitations (24 hour Holter monitor showed ventricular ectopics). The patient was started on deltiazem 40 mg tid. She developed progressive dyspnea, chocking sensation and cough. The patient started to have abdominal distension, constipation and dysphagia to solids. Arthritis of the knee started to occur with puffiness of the hands and 10 minute morning stiffness and eventually she was unable to close a fist (Her sister has rheumatoid arthritis). She started to feel proximal weakness on going upstairs (grade 4 muscle power). The menstrual cycle became irregular and there would be urgency of urine. Laboratory investigations of the patient are shown in Table 1. The case study conforms to the 1995 Helsinki declaration and the patients gave an informed consent.

There was pitting edema of extremities, peripheral skin tightness, coldness and Raynauds with sluggish peripheral circulation. Skin tightness was increased as reflected by the increased modified Rodnan total skin score (MRSS) which was 37. Multiple purpuric eruptions were present on the legs and of variable sizes (Figure 1). Skin biopsy histopathology proved small vessel (leucocytoclastic) vasculitis of the purpuric rash. The patient had a positive hepatitis C virus (HCV) test by PCR and positive cryoglobulinemia. The pulmonary function test was consistent with a restrictive pattern with progressive deterioration (FEV1 (58.2%), FVC (64.7%), DLCO (16.9%) and FEV1/FVC (74.5%) compared to the results of her preceding follow-up. Transesophageal echocardiography revealed pulmonary hypertension (RVSP 60 mmHg), EF (63%) with moderate pericardial effusion which were verified by a non-contrast CT chest.
Table 1

Laboratory features of the diffuse cutaneous systemic sclerosis patients with pulmonary hypertension and small vessel (cryoglobulinemic) vasculitic rash

Laboratory investigations

Hb (g/dl)

15.6

WBC (×103/mm3)

5.6

Platelets (×103/mm3)

246

CK (U/L)

81

LDH (U/L)

691

ESR (mm/1st hr)

114

Sodium (mmol/L)

142

Potassium (mmol/L)

3.8

Calcium (mg/dl)

9.2

Phosphorus (mg/dl)

3.3

PT (seconds)

17

INR

1.4

PTT (seconds)

34.3

Triglycerides (mg/dl)

102

Cholesterol (mg/dl)

127

Cholesterol/HDL

4.4

LDL/HDL

2.7

AST (U/L)

19

ALT (U/L)

7

ALP (IU/L)

59

Creatinine (mg/dl)

0.6

Urea (mg/dl)

9

SUA (mg/dl)

6.4

RF

Negative

ANA

Positive (1:40) homogeneous

Anti-ds DNA

Negative

Anti-Scl-70

Positive

Anticentromere

Negative

U1RNP

negative

Anti-Ro (U/ml)

Positive (28.2)

Anti-La (U/ml)

Positive (17.9)

ANCA

Negative

Cryoglobulinemia

Positive

HCV (PCR)

Positive

Hb: Hemoglobin, WBC: White blood cells count, CK: creatine kinase, LDH: lactate dehydrogenase, ESR: Erythrocyte sedimentation rate, PT: prothrombin time, INR: Inverse neutralization ratio, PTT: partial thromboplastin time, LDL: low density lipoprotein, HDL: high density lipoprotein, AST: Aspartate transaminase, ALT: alanine transaminase, SUA: serum uric acid, RBF: rheumatoid factor, ANA: antinuclear antibody, ds DNA: double stranded deoxyribonucleic acid, Scl-70: scleroderma 70, U1RNP: Uridine 1 ribonucleoprotein, ANCA: antineutrophil cytoplasmic antibody, HCV: hepatitis C virus.

Figure 1

Purpuric skin rash (small vessel vasculitis) in a 40 year old female with diffuse cutaneous systemic sclerosis (dcSSc) and pulmonary arterial hypertension (PAH) before (left) and after (right) treatment with sildenafil.

The patient was prescribed prednisolone 40 mg/day, warfarin 3 mg/day, furosemide 20 mg with spironolactone 100 mg, verapamil 120 mg/day. In addition, the patient received a daily dose of omeprazole 40 mg, domperidone 10 mg before the main meal, simethicone chew tablets, calcium carbonate 500 mg and colchicines 0.5 mg twice daily for a month. There was slight improvement of the dyspnea and skin rash while all other symptoms persisted. The ESR was reduced from 114 to be 85 mm/1st hr.

One week later it was decided to add sildenafil 50 mg/day with a remarkable improvement of the dyspnea and Raynauds’ with a reduction of the peripheral edema as well as a significant improvement of the skin tightness as the MRSS became 22. The small vessel vasculitic rash remarkably improved (Figure). The pulmonary function tests significantly improved: FEV1 77%, FVC 79.2%, DLCO 45.2%, FEV1/FVC 88.6. The echocardiography results were enhanced with an EF 73% and a reduction of the pericardial effusion. The RVSP became 34 mmHg with a dramatic improvement of the pulmonary hypertension. The patient significantly improved with a favorable clinical and functional outcome on the regular follow ups for the following year.

Using a selective pulmonary vasodilator as sildenafil contributes to the significant improvement of the clinical conditions and pulmonary hemodynamics which benefits patients with severe pulmonary hypertension resistant to conventional therapy (Catapano-Minotti et al. 2008; Shahin 2006). The pulmonary arterial hypertension associated with connective tissue disease is difficult to manage, and has a poor prognosis. The PDE5 inhibitor ‘sildenafil’ enhances vasodilatation, has antiproliferative effects, and is effective in the treatment of PAH (Badesch et al. 2007). The vasculopathy associated with SSc is considered noninflammatory, yet frank vasculitis can complicate it posing diagnostic and therapeutic challenges (Kao and Weyand 2010).

We report a very rare association of dcSSc with small vessel cryoglobulinemic vasculitis. It has been reported that cryoglobulinemic vasculitis is rarely encountered in SSc patients (Kao and Weyand 2010). The remarkable improvement in the vasculitic skin lesions in this case after sildenafil is the second report after the described dramatic improvement of small vessel vasculitis in a case with Takayasu arteritis (Uthman and Chaaban 2006). The emerging trends make it necessary to exploit the full therapeutic potential of this class of drugs ‘sildenafil’ in scleroderma and PAH with other extrapulmonary manifestations.

Declarations

Authors’ Affiliations

(1)
Rheumatology and Clinical Immunology, Faculty of Medicine, Cairo University
(2)
Internal Medicine, University of Texas Health Science Center
(3)
Pharmacology, Royal College of Surgeons
(4)
Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University

References

  1. Badesch DB, Hill NS, Burgess G, Rubin LJ, Barst RJ, Galiè N, Simonneau G, SUPER Study Group: Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007, 34(12):2417-2422.Google Scholar
  2. Catapano-Minotti G, Corsonello A, Guadalupi G, Spani R, Antonelli-Incalzi R: Treatment of severe pulmonary hypertension secondary to scleroderma: a three-drug approach. Intern Med 2008, 47(6):511-513. 10.2169/internalmedicine.47.0565View ArticleGoogle Scholar
  3. Kao L, Weyand C: Vasculitis in systemic sclerosis. Int J Rheumatol 2010, 2010: 385938.View ArticleGoogle Scholar
  4. Shahin AA: Pulmonary involvement in systemic sclerosis. Treat Respir Med 2006, 5(6):429-436. 10.2165/00151829-200605060-00008View ArticleGoogle Scholar
  5. Uthman IW, Chaaban H: The use of sildenafil in pediatric Takayasu arteritis. Clin Rheumatol 2006, 25(4):550. 10.1007/s10067-005-0054-8View ArticleGoogle Scholar

Copyright

© Gheita et al.; licensee Springer. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.